EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 03/04/26
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 03/02/26
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026GlobeNewsWire • 02/25/26
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?Zacks Investment Research • 02/18/26
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026GlobeNewsWire • 01/07/26
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular DegenerationGlobeNewsWire • 11/19/25
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/05/25
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 11/05/25
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal StudyBenzinga • 10/15/25
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular EdemaGlobeNewsWire • 10/14/25
EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/02/25